ArticleJournal of clinical apheresis2026
Therapeutic Plasma Exchange in the Elderly: Rare Indications but Good Tolerability.
Article in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic plasma exchange (TPE) is used for a wide range of indications and is associated with well-described adverse events. However, no study has specifically focused on tolerance in elderly patients, despite its expected increasing use in this population. We conducted a single-center retrospective case-control study of all patients aged ≥ 75 years who underwent TPE between 2011 and 2023. Adverse events were identified through standardized surveillance forms completed contemporaneously. The primary outcome was the rate of any adverse event occurring during TPE sessions, compared between patients aged ≥ 75 years (elderly group) and those < 75 years. Elderly patients accounted for 7.4% of all TPE sessions during the study period. Thirty-one patients were included in each group, corresponding to 506 TPE sessions. Hypertension and cardiac disease were significantly more frequent in the elderly group. Overall adverse event rates were similar in the two groups (40.6% in < 75 years vs. 43.4% in ≥ 75 years, p = 0.592). Asymptomatic hypocalcemia was more frequent in elderly patients, whereas allergic reactions were more frequent in younger patients. One-year survival did not differ between groups (p = 0.31). TPE in patients aged ≥ 75 years is uncommon, but its tolerance is comparable to that of younger patients. When clinically indicated, TPE should not be withheld on the basis of age alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.